Kazakhstan vs Mozambique: Average cost of tuberculosis treatment by type
Kazakhstan
24 constant 2022 US$
in 2023
Mozambique
22 constant 2022 US$
in 2024
Kazakhstan rank
20th
Mozambique rank
22nd
Average cost of tuberculosis treatment by type over time
- Kazakhstan
- Mozambique
How they compare
Kazakhstan currently reports 24 constant 2022 US$ against 22 constant 2022 US$ in Mozambique, a difference of 2 constant 2022 US$.
That makes Kazakhstan's figure about 1.1 times Mozambique's.
The two have swapped places 3 times across 5 shared years of data; in 2019 it was Mozambique ahead.
Kazakhstan ranks 20th and Mozambique ranks 22nd of 62 countries.
Mozambique has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20 constant 2022 US$ | 25 constant 2022 US$ | 5 constant 2022 US$ | Mozambique |
| 2020s | 25.5 constant 2022 US$ | 29.75 constant 2022 US$ | 4.25 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of tuberculosis treatment by type, Kazakhstan or Mozambique?
- Kazakhstan, at 24 constant 2022 US$ against 22 constant 2022 US$ in Mozambique as of 2023.
- What is the difference in average cost of tuberculosis treatment by type between Kazakhstan and Mozambique?
- 2 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Mozambique?
- 5 years are reported by both, from 2019 to 2023.
- How do Kazakhstan and Mozambique rank globally for average cost of tuberculosis treatment by type?
- Kazakhstan ranks 20th and Mozambique ranks 22nd of 62 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of tuberculosis treatment by type. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per person starting tuberculosis preventive treatment, excluding buffer stock.